Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence

Rong Liang Shi, Ning Qu, Ting Xian Luo, Jun Xiang, Tian Liao, Guo Hua Sun, Yu Wang, Yu Long Wang, Cai Ping Huang, Qing Hai Ji

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Programmed death-ligand 1 (PD-L1) expression has been reported in several malignancies, but the expression of PD-L1 in papillary thyroid cancer (PTC) has been characterized rarely. The aim of this study was to assess the significance of PD-L1 expression and its associations with clinicopathologic factors and disease outcome in PTC. Methods: Immunohistochemistry staining was conducted retrospectively to evaluate the expression of PD-L1 in a total of 260 PTC tumors and corresponding non-tumor tissues. The correlations between PD-L1 expressions with clinicopathologic features and recurrence-free survival (RFS) were analyzed. Results: PD-L1 expression was positive in 52.3% (136/260) of PTC tumor tissues, which was significantly higher than in corresponding non-tumor thyroid tissues. In clinicopathologic analyses, this positive staining of PD-L1 was positively linked to multifocality (p = 0.001) and extrathyroidal extension (p = 0.001). In multivariate Cox regression analysis, positive PD-L1 expression in tumor tissue was significantly associated with worse RFS (hazard ratio 2.825 [confidence interval 1.149-6.943], p = 0.024). In subgroup analyses based on clinicopathologic factors, positive PD-L1 staining of tumor tissue was associated with worse RFS in males (p = 0.001), older patients (≥45 years; p = 0.001), and patients with a primary tumor size >4 cm (p = 0.002), multifocal tumors (p = 0.031), extrathyroidal extension (p = 0.012), and lymph node metastasis (p = 0.004). In contrast, positive PD-L1 staining predicted worse RFS in the subgroup of patients without Hashimoto's thyroiditis (p = 0.001) and treated with total thyroidectomy (p = 0.019). Conclusions: PD-L1 is important in determining aggressiveness of PTC and could predict the prognosis of patients. Therefore, inhibition of PD-L1 is suggested as a potential strategy for the treatment of advanced PTC with high expression of PD-L1.

Original languageEnglish (US)
Pages (from-to)537-545
Number of pages9
JournalThyroid
Volume27
Issue number4
DOIs
StatePublished - Apr 2017

Fingerprint

Ligands
Recurrence
Neoplasms
Staining and Labeling
Survival
Papillary Thyroid cancer
Hashimoto Disease
Thyroidectomy
Thyroid Gland
Lymph Nodes
Immunohistochemistry
Regression Analysis
Confidence Intervals
Neoplasm Metastasis

Keywords

  • biological marker
  • papillary thyroid cancer
  • programmed death-ligand 1
  • survival analysis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence. / Shi, Rong Liang; Qu, Ning; Luo, Ting Xian; Xiang, Jun; Liao, Tian; Sun, Guo Hua; Wang, Yu; Wang, Yu Long; Huang, Cai Ping; Ji, Qing Hai.

In: Thyroid, Vol. 27, No. 4, 04.2017, p. 537-545.

Research output: Contribution to journalArticle

Shi, RL, Qu, N, Luo, TX, Xiang, J, Liao, T, Sun, GH, Wang, Y, Wang, YL, Huang, CP & Ji, QH 2017, 'Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence', Thyroid, vol. 27, no. 4, pp. 537-545. https://doi.org/10.1089/thy.2016.0228
Shi, Rong Liang ; Qu, Ning ; Luo, Ting Xian ; Xiang, Jun ; Liao, Tian ; Sun, Guo Hua ; Wang, Yu ; Wang, Yu Long ; Huang, Cai Ping ; Ji, Qing Hai. / Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence. In: Thyroid. 2017 ; Vol. 27, No. 4. pp. 537-545.
@article{5bbf8c06625c496d94d3fc0bba9708d9,
title = "Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence",
abstract = "Background: Programmed death-ligand 1 (PD-L1) expression has been reported in several malignancies, but the expression of PD-L1 in papillary thyroid cancer (PTC) has been characterized rarely. The aim of this study was to assess the significance of PD-L1 expression and its associations with clinicopathologic factors and disease outcome in PTC. Methods: Immunohistochemistry staining was conducted retrospectively to evaluate the expression of PD-L1 in a total of 260 PTC tumors and corresponding non-tumor tissues. The correlations between PD-L1 expressions with clinicopathologic features and recurrence-free survival (RFS) were analyzed. Results: PD-L1 expression was positive in 52.3{\%} (136/260) of PTC tumor tissues, which was significantly higher than in corresponding non-tumor thyroid tissues. In clinicopathologic analyses, this positive staining of PD-L1 was positively linked to multifocality (p = 0.001) and extrathyroidal extension (p = 0.001). In multivariate Cox regression analysis, positive PD-L1 expression in tumor tissue was significantly associated with worse RFS (hazard ratio 2.825 [confidence interval 1.149-6.943], p = 0.024). In subgroup analyses based on clinicopathologic factors, positive PD-L1 staining of tumor tissue was associated with worse RFS in males (p = 0.001), older patients (≥45 years; p = 0.001), and patients with a primary tumor size >4 cm (p = 0.002), multifocal tumors (p = 0.031), extrathyroidal extension (p = 0.012), and lymph node metastasis (p = 0.004). In contrast, positive PD-L1 staining predicted worse RFS in the subgroup of patients without Hashimoto's thyroiditis (p = 0.001) and treated with total thyroidectomy (p = 0.019). Conclusions: PD-L1 is important in determining aggressiveness of PTC and could predict the prognosis of patients. Therefore, inhibition of PD-L1 is suggested as a potential strategy for the treatment of advanced PTC with high expression of PD-L1.",
keywords = "biological marker, papillary thyroid cancer, programmed death-ligand 1, survival analysis",
author = "Shi, {Rong Liang} and Ning Qu and Luo, {Ting Xian} and Jun Xiang and Tian Liao and Sun, {Guo Hua} and Yu Wang and Wang, {Yu Long} and Huang, {Cai Ping} and Ji, {Qing Hai}",
year = "2017",
month = "4",
doi = "10.1089/thy.2016.0228",
language = "English (US)",
volume = "27",
pages = "537--545",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence

AU - Shi, Rong Liang

AU - Qu, Ning

AU - Luo, Ting Xian

AU - Xiang, Jun

AU - Liao, Tian

AU - Sun, Guo Hua

AU - Wang, Yu

AU - Wang, Yu Long

AU - Huang, Cai Ping

AU - Ji, Qing Hai

PY - 2017/4

Y1 - 2017/4

N2 - Background: Programmed death-ligand 1 (PD-L1) expression has been reported in several malignancies, but the expression of PD-L1 in papillary thyroid cancer (PTC) has been characterized rarely. The aim of this study was to assess the significance of PD-L1 expression and its associations with clinicopathologic factors and disease outcome in PTC. Methods: Immunohistochemistry staining was conducted retrospectively to evaluate the expression of PD-L1 in a total of 260 PTC tumors and corresponding non-tumor tissues. The correlations between PD-L1 expressions with clinicopathologic features and recurrence-free survival (RFS) were analyzed. Results: PD-L1 expression was positive in 52.3% (136/260) of PTC tumor tissues, which was significantly higher than in corresponding non-tumor thyroid tissues. In clinicopathologic analyses, this positive staining of PD-L1 was positively linked to multifocality (p = 0.001) and extrathyroidal extension (p = 0.001). In multivariate Cox regression analysis, positive PD-L1 expression in tumor tissue was significantly associated with worse RFS (hazard ratio 2.825 [confidence interval 1.149-6.943], p = 0.024). In subgroup analyses based on clinicopathologic factors, positive PD-L1 staining of tumor tissue was associated with worse RFS in males (p = 0.001), older patients (≥45 years; p = 0.001), and patients with a primary tumor size >4 cm (p = 0.002), multifocal tumors (p = 0.031), extrathyroidal extension (p = 0.012), and lymph node metastasis (p = 0.004). In contrast, positive PD-L1 staining predicted worse RFS in the subgroup of patients without Hashimoto's thyroiditis (p = 0.001) and treated with total thyroidectomy (p = 0.019). Conclusions: PD-L1 is important in determining aggressiveness of PTC and could predict the prognosis of patients. Therefore, inhibition of PD-L1 is suggested as a potential strategy for the treatment of advanced PTC with high expression of PD-L1.

AB - Background: Programmed death-ligand 1 (PD-L1) expression has been reported in several malignancies, but the expression of PD-L1 in papillary thyroid cancer (PTC) has been characterized rarely. The aim of this study was to assess the significance of PD-L1 expression and its associations with clinicopathologic factors and disease outcome in PTC. Methods: Immunohistochemistry staining was conducted retrospectively to evaluate the expression of PD-L1 in a total of 260 PTC tumors and corresponding non-tumor tissues. The correlations between PD-L1 expressions with clinicopathologic features and recurrence-free survival (RFS) were analyzed. Results: PD-L1 expression was positive in 52.3% (136/260) of PTC tumor tissues, which was significantly higher than in corresponding non-tumor thyroid tissues. In clinicopathologic analyses, this positive staining of PD-L1 was positively linked to multifocality (p = 0.001) and extrathyroidal extension (p = 0.001). In multivariate Cox regression analysis, positive PD-L1 expression in tumor tissue was significantly associated with worse RFS (hazard ratio 2.825 [confidence interval 1.149-6.943], p = 0.024). In subgroup analyses based on clinicopathologic factors, positive PD-L1 staining of tumor tissue was associated with worse RFS in males (p = 0.001), older patients (≥45 years; p = 0.001), and patients with a primary tumor size >4 cm (p = 0.002), multifocal tumors (p = 0.031), extrathyroidal extension (p = 0.012), and lymph node metastasis (p = 0.004). In contrast, positive PD-L1 staining predicted worse RFS in the subgroup of patients without Hashimoto's thyroiditis (p = 0.001) and treated with total thyroidectomy (p = 0.019). Conclusions: PD-L1 is important in determining aggressiveness of PTC and could predict the prognosis of patients. Therefore, inhibition of PD-L1 is suggested as a potential strategy for the treatment of advanced PTC with high expression of PD-L1.

KW - biological marker

KW - papillary thyroid cancer

KW - programmed death-ligand 1

KW - survival analysis

UR - http://www.scopus.com/inward/record.url?scp=85017095143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017095143&partnerID=8YFLogxK

U2 - 10.1089/thy.2016.0228

DO - 10.1089/thy.2016.0228

M3 - Article

C2 - 27825291

AN - SCOPUS:85017095143

VL - 27

SP - 537

EP - 545

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 4

ER -